Cardiovascular pharmacology: an update

Anesthesiol Clin. 2010 Dec;28(4):723-38. doi: 10.1016/j.anclin.2010.09.001.

Abstract

Cardiovascular diseases are a leading cause of hospitalizations and death in the United States and elsewhere in the world. Developing new therapeutic agents for cardiovascular diseases has always been the priority for the pharmaceutical industry because of the huge potential market for these drugs. Some of these newer drugs are frequently used in the practice of cardiovascular anesthesiology. This article reviews the recent advances in cardiovascular medications related to the practice of cardiac anesthesia.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Agents / pharmacology*
  • Cardiovascular Agents / therapeutic use
  • Cardiovascular Diseases / drug therapy*
  • Diastole / drug effects
  • Heart Failure / drug therapy
  • Humans
  • Hydrazones / pharmacology
  • Hydrazones / therapeutic use
  • Muscle Contraction / drug effects
  • Myofibrils / ultrastructure
  • Natriuretic Peptide, Brain / therapeutic use
  • Nicardipine / pharmacology
  • Nicardipine / therapeutic use
  • Pyridazines / pharmacology
  • Pyridazines / therapeutic use
  • Pyridines / pharmacology
  • Pyridines / therapeutic use
  • Sarcomeres / ultrastructure
  • Simendan
  • Urea / analogs & derivatives
  • Urea / pharmacology
  • Urea / therapeutic use

Substances

  • Cardiovascular Agents
  • Hydrazones
  • Pyridazines
  • Pyridines
  • Natriuretic Peptide, Brain
  • clevidipine
  • omecamtiv mecarbil
  • Simendan
  • Urea
  • Nicardipine